Pediatric Leukemia and Lymphoma Steering Committee
The Pediatric Leukemia and Lymphoma Steering Committee (PLLSC) was established in 2011. PLLSC members include representatives from the Children's Oncology Group, pediatric and medical oncologists and other specialists, translational scientists, biostatisticians, patient advocates, and NCI staff.
The PLLSC follows a data-driven, transparent process to identify and promote the "Best Science" in clinical research for pediatric and adolescent patients with leukemia, lymphoma, and other hematologic malignancies by evaluating and prioritizing phase 2 and phase 3 clinical trial concepts.
- MRD Working Group – November 2012
The following are clinical trials that were approved at the concept stage by the Steering Committee:
|Trial ID||NCT ID||Trial Title|
|COG-ANHL1131||NCT01516580||Intergroup Randomized Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or B-Acute Leukemia (B-AL): Rituximab Evaluation in High Risk Patients|
|COG-ASCT1221||NCT01824693||A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myeolomonocytic Leukemia (JMML)|
|COG-ANHL12P1||NCT01979536||A Pilot Study of Brentuximab Vedotin and Crizotinib in Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma|
CCCT Contact: Wolf Lindwasser, Ph.D.